SCHEMBL4629491

SCHEMBL4629491

CC1CC(=O)N[C@@H]1C(=O)O

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ITGB1 P05556 2/20 0.42
ITGA5 P08648 2/20 0.42
ITGB3 P05106 1/20 0.42
ITGB2 P05107 1/20 0.42
ITGAV P06756 1/20 0.42
ITGA2B P08514 1/20 0.42
ITGB5 P18084 1/20 0.42
ITGAL P20701 1/20 0.42
IDUA P35475 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
ALDH1A1 P00352 3/20 0.35
LMNA P02545 2/20 0.35
CRBN Q96SW2 1/20 0.34
POLB P06746 1/20 0.33
BRD4 O60885 3/20 0.32
CREBBP Q92793 2/20 0.32
EP300 Q09472 1/20 0.32
CAD P27708 1/20 0.32
HTT P42858 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31697657 1.00 ITGB1 (0.42) ITGB1ITGA5ITGB3ITGB2ITGAV
SCHEMBL4629492 1.00 ITGB1 (0.42) ITGB1ITGA5ITGB3ITGB2ITGAV
SCHEMBL19850672 1.00 ITGB1 (0.42) ITGB1ITGA5ITGB3ITGB2ITGAV
SCHEMBL7282443 1.00 ITGB1 (0.42) ITGB1ITGA5ITGB3ITGB2ITGAV
SCHEMBL7330767 1.00 ITGB1 (0.42) ITGB1ITGA5ITGB3ITGB2ITGAV
SCHEMBL31694886 1.00 ITGB1 (0.42) ITGB1ITGA5ITGB3ITGB2ITGAV
SCHEMBL9747922 0.79 IDUA (0.34) ITGB1ITGA5ITGB3ITGB2ITGAV
SCHEMBL10411814 0.78 ALDH1A1 (0.41) ITGB1ITGA5ITGB3ITGB2ITGAV
SCHEMBL14551177 0.78 ALDH1A1 (0.41) ITGB1ITGA5ITGB3ITGB2ITGAV
SCHEMBL12974414 0.77 CRBN (0.33) ITGB1ITGA5ITGB3ITGB2ITGAV

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12371454-B2 Cyclic peptide compound having Kras inhibitory action CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-07-29 US disclosed
WO-2025073270-A1 BIPHENYL TETRAHYDROPYRROLE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF 海南因瑞生物医药科技有限公司 2025-04-10 WO disclosed
US-20240400617-A1 CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2024-12-05 US disclosed
US-20240148821-A1 PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2024-05-09 US disclosed
EP-4316503-A1 PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2024-02-07 EP disclosed
CN-117327000-A Biphenyl tetrahydropyrrole compound and preparation method and application thereof 海南因瑞生物医药科技有限公司 2024-01-02 CN disclosed
CN-117279655-A Pharmaceutical use of cyclic peptide compounds 中外制药株式会社 2023-12-22 CN disclosed
US-20230151060-A1 CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-05-18 US disclosed
WO-2022234852-A1 PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND 中外製薬株式会社 2022-11-10 WO disclosed
EP-4043478-A1 CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITING ACTION CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2022-08-17 EP disclosed
CN-101896570-A Method, obtainable isocyanate-group-terminated poly-adduct and uses thereof thus of the polymkeric substance of preparation hydroxyl-functional SIKA TECHNOLOGY AG 2010-11-24 CN disclosed
US-20080108830-A1 Production method of optically active 2-[(N-benzylprolyl)amino]benzo-phenone compound AJINOMOTO CO. INC (JP) 2008-05-08 US disclosed
EP-1918276-A1 Production method of optically active 2- [ (N-Benzylprolyl) Amino ] Benzophenone compound Ajinomoto Co., Inc. (JP) 2008-05-07 EP disclosed
CN-1956943-A Catalytic asymmetric desymmetrization of prochiral and meso cyclic anhydrides UNIV BRANDEIS (US) 2007-05-02 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230151060-A1 CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION KRAS, NRAS, HRAS ITGB1 4791/4885ITGA5 4805/4885ITGB3 4849/4885
US-20240400617-A1 CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION KRAS, NRAS, HRAS ITGB1 4791/4885ITGA5 4805/4885ITGB3 4849/4885
US-20080108830-A1 Production method of optically active 2-[(N-benzylprolyl)amino]benzo-phenone compound NPEPPS, SYMPK, REN ITGB1 4499/4885ITGA5 3077/4885ITGB3 4285/4885
US-20240148821-A1 PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND VIP, IAPP, KRAS ITGB1 4797/4885ITGA5 4640/4885ITGB3 4650/4885
US-12371454-B2 Cyclic peptide compound having Kras inhibitory action KRAS, NRAS, HRAS ITGB1 4791/4885ITGA5 4805/4885ITGB3 4849/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.